CombinatoRx Diabetes Drug Shows Promise

5/27/09

CombinatoRx (NASDAQ:CRXX) reports that its Type 2 diabetes treatment, a combination of bezafibrate and diflunisal, provided statistically significant reduction in blood sugar levels and other benefits in a mid-stage clinical trial. It’s a bit of good news for Cambridge, MA-based CombinatoRx after it revealed last October that its lead arthritis drug failed in a Phase II trial.

Next Post

Related Topics

Related Posts

Xconomy Events Across the Network

The Napa Summit 2013: New Rules for Growth

San Francisco · 6/3/13

More Xconomy Events

Xconomy’s Most Popular

  1. Henri Termeer on Startups, Drug Prices, Getting Older (Part 1)
  2. Nine Lessons for Innovators from a Nobel Prize-Winning Psychologist
  3. Xconomy Opens in Texas, Expanding Roundup of Innovation Across U.S.
  4. Life After PowerPoint: Prezi Zooms Ahead in Digital Storytelling
  5. Zillions of Biotech Conferences Want You. Which Should You Attend?

Xconomy on Demand

Did you miss something? Don't despair…

Xconomy offers a number of ways to subscribe for free!

Subscribe Now
IDG Tech Network
Protected by Mozy
Eventbrite - events made easy

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York, Boulder/Denver, Texas and beyond.

© 2007-2013, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.

Website development support from Andrew Koyfman with design support from Rob Hunter.